BeiGene
BGNE
#934
Rank
โ‚ฌ19.96 B
Marketcap
179,48ย โ‚ฌ
Share price
-2.10%
Change (1 day)
-0.87%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -โ‚ฌ0.82 Billion

According to BeiGene 's latest financial reports the company's current earnings are โ‚ฌ3.09 Billion. In 2023 the company made an earning of -โ‚ฌ1.15 Billion, an increase over its 2022 earnings that were of -โ‚ฌ1.7 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -โ‚ฌ0.82 Billion-28.79%
2023 -โ‚ฌ1.15 Billion-32.52%
2022 -โ‚ฌ1.7 Billion24.39%
2021 -โ‚ฌ1.37 Billion-13.21%
2020 -โ‚ฌ1.58 Billion72.69%
2019 -โ‚ฌ0.92 Billion36.01%
2018 -โ‚ฌ0.67 Billion616.83%
2017 -โ‚ฌ93.39 Million-15.24%
2016 -โ‚ฌ0.12 Billion107.91%
2015 -โ‚ฌ53 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-โ‚ฌ17.23 Million-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚ฌ0.24 Billion-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA